Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK ...
Venture investors continue to plow billions of dollars into human resources software, Crunchbase data shows. While funding is ...
It could wind up costing all Americans money. New report divulges industry secret about Google's AI Gemini: 'It's a wake-up call' first appeared on The Cool Down.